Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the first proven ERA therapy to show reduction in morbidity and mortality in patients diagnosed with PAH. This presentation covers the pharmacology and key studies of macitentan.
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH
-
Treatment for chronic hepatitis C has evolved rapidly from an interferon based regimen of...
-
A careful clinical judgment is required in order to choose between enzyme-inducing...
-
Retinal detachment is the separation of retina from underlying tissue within the eye. Most of...
-
Allergic rhinitis (AR) is a very common disease with a steadily increasing prevalence. It has a...